PT - JOURNAL ARTICLE AU - Anni Gålne AU - Helen Almquist AU - Martin Almquist AU - Cecilia Hindorf AU - Tomas Ohlsson AU - Erik Nordenström AU - Anna Sundlöv AU - Elin Trägårdh TI - A Prospective Observational Study to Evaluate the Effects of Long-Acting Somatostatin Analogs on <sup>68</sup>Ga-DOTATATE Uptake in Patients with Neuroendocrine Tumors AID - 10.2967/jnumed.119.226332 DP - 2019 Dec 01 TA - Journal of Nuclear Medicine PG - 1717--1723 VI - 60 IP - 12 4099 - http://jnm.snmjournals.org/content/60/12/1717.short 4100 - http://jnm.snmjournals.org/content/60/12/1717.full SO - J Nucl Med2019 Dec 01; 60 AB - Patients with neuroendocrine tumors (NETs) are often treated with somatostatin analogs (SSAs) for control of symptoms and tumor growth. Such therapy could theoretically lead to misinterpretation of somatostatin receptor imaging with 68Ga-DOTATATE PET/CT by interfering with tracer–receptor binding. Guidelines recommend an interval of 3–4 wk between the last dose and imaging. The aim of this study was to evaluate if long-acting (LA) SSA treatment changes the uptake of 68Ga-DOTATATE in patients with NETs. Methods: From 2013 to 2016, 296 patients with, or under evaluation for, NETs were included in this prospective observational study. The effect of LA SSA on tracer uptake was evaluated in 2 main patient populations: those undergoing 68Ga-DOTATATE PET/CT before starting LA SSA treatment and at least once afterward, and those receiving ongoing LA SSA therapy, in whom the effect of the interval between the last dose of LA SSA and the PET/CT exam was analyzed. A third, explorative, analysis was performed to evaluate if clinical disease progression, regression, or stable tumor status changed the uptake of 68Ga-DOTATATE. In the 3 analyses, measurements of SUVmax in normal liver and tumor lesions were compared. Results: The median SUVmax in normal liver was significantly higher before treatment (8.6; interquartile range, 7.4–10.2) than after treatment initiation (6.0; 4.7–8.0) (P &lt; 0.001). No significant changes in SUVmax were seen in tumor lesions after treatment initiation. No significant differences in SUVmax were found in normal liver or tumor lesions dependent on the interval between last dose of LA SSA and PET/CT. Conclusion: Treatment with LA SSA does not change SUVmax in tumor lesions, whereas SUVmax in normal liver is significantly lower after treatment. The findings have implications for interpretation of 68Ga-DOTATATE PET/CT for response assessment after SSA therapy and for guidelines on discontinuation of treatment before PET/CT.